Solspan UK’s Post

Earth-Friendly Pharma: “The connectivity between the health of people and an healthy planet” Full respect and admiration for this Pam Cheng!

Did you know that, according to Reuters, the healthcare industry is responsible for nearly 5% of global emissions? Following COP28, medical equipment manufacturers and pharmaceutical companies have begun working together to address the industry’s emissions issue. Whether through power purchase agreements for renewable energy or better ways to calculate emissions, this is an excellent example of cross-sector collaboration in shifting to more sustainable methods and resources. #emissions #renewableenergy #netzeroemissions Read more here: https://lnkd.in/e_H6tMvj

This week, our colleague Sebastian Herrmann joined the conversation at the Future in Pharmaceuticals Ireland event as one of the keynote speakers, delving into the topic of "Smart Infrastructure in the Pharmaceutical Manufacturing Sector". While it is great to see that the Irish pharmaceutical industry is already making progress in reducing greenhouse gas emissions, there are still actions to be taken in the areas of biodiversity, waste management, water conservation and other important levers. Thus, there remains a long way to go, especially to prepare for increasing legislative pressure, including carbon taxation. 🌱 For pharma companies the following actions will be critical in the future: ➡️ Developing a clear sustainability roadmap supported by the right cultural narrative to bring the entire organization along on this journey ➡️ Breaking down the roadmap into actionable site-level projects starting with energy consumption reduction measures, increasing the level of electrification, renewable power onsite generation, PPAs and carbon offsetting ➡️ Increasing transparency on scope 3 emissions along the supply chain to accurately measure the product carbon footprint based on dynamic values ➡️ Establishing relevant KPIs, governance structures, and incentives to effectively measure and manage the sustainability efforts long-term Let's take action together and conduct a sustainability assessment in your sites to find immediate measures and build positive momentum if you are at the beginning, or review your journey and accelerate progress if you are already further along. 🌍 #SiemensAdvanta #SiemensAdvantaConsulting #FutureInPharmaceuticals #Sustainability

With supply chains across the pharma industry a major carbon contributor, businesses across the sector are looking to innovative solutions to help them prioritise using green energy and embrace eco-friendly practices. 🌿 But can the pharma industry really reduce their environmental impact and save the health of our planet? #Atradius #cleanenergy #pharma #sustainability #carbonemissions #supplychain

Did you know? Healthcare's carbon footprint is more significant than you might think, making up 4-5% of global greenhouse gas emissions. With environmental awareness on the rise, learn how the sector plans to address its impact in the future! Our UK partner FIECON has compiled all the relevant information in a corresponding blog post, which you can find below.  #PHAROSHealthcareConsulting #FIECON #Update #HTA #MarketAccess #EU #Sustainability 

Prediction: Sustainability will be assessed as a value parameter in life sciences appraisal by the year 2030. Special thanks to Zuzanna Opuchlik and Rushab Shah for authoring this great piece!

Did you know? - The pharmaceutical sector's GHG emissions are higher than the automotive industry, so how are pharma companies addressing sustainability and climate change? In this article, Cority's Sean Baldry, CRSP adds his perspective on the problem and what needs to be done - and it's gonna take a village. https://lnkd.in/eUzfGGWf #sustainability #climatechange #EmpowerBetter

The pharmaceutical industry, responsible for a third of the healthcare sector's greenhouse-gas emissions, faces hurdles in reducing its carbon footprint. Western companies recognize the need for fundamental changes and stress the importance of an Earth Responsibility Score (ERS). Scope 3 Emissions and ERS Impact: Pharmaceutical companies, committed to carbon reduction, grapple with the complex challenge of Scope 3 emissions tied to supply chains and product usage. A robust Earth Responsibility Score is crucial for evaluating their commitment to environmental mitigation across all operational facets. Regulatory Processes and ERS Dynamics: Striving for net-zero emissions by 2050, Earth Responsibility Scores could dynamically reflect the industry's progress, considering regulatory processes impacting emission reduction agility. An ERS nuances the evaluation of the industry's commitment to sustainability. Heat and Electricity Challenges: A substantial portion (50-80%) of biopharma emissions results from high-temperature processes and electricity-intensive operations. Earth Responsibility Scores closely monitor efforts to address these challenges in supplier networks, ensuring transparency and accountability. Industry Collaboration and Global ERS Impact: Collaborative initiatives, like the Sustainable Markets Initiative Health Systems Task Force, showcase the industry's commitment to emissions reduction. Yet, addressing emissions in supplier networks, especially in countries like China and India, necessitates a global Earth Responsibility Score perspective. The industry's progress can be acknowledged within the ERS framework. Countries' Role in Sustainable Healthcare and ERS Impact: Nations committing to low-carbon health systems align with ERS goals, making an Earth Responsibility Score a valuable tool to measure and incentivize industry-wide sustainability. The industry's journey is interconnected with the collective Earth Responsibility Scores, emphasizing the global responsibility to reduce greenhouse gas emissions. In conclusion, the pharmaceutical industry's pursuit of sustainability demands a harmonized effort, innovation focus, and an Earth Responsibility Score framework for transparent and accountable reductions in greenhouse gas emissions. The Wall Street Journal #PharmaceuticalIndustry #ERS #EarthResponsibilityScores #Sustainability #ClimateAction #HealthcareInnovation

THIS IS WHY ECO-FRIENDLY EXCIPIENTS ARE A GAME CHANGER IN PHARMACEUTICALS! 🌿 Choosing eco-friendly excipients in pharmaceuticals brings numerous advantages for both the environment and your health. Here are five key benefits: 1. Environmental Sustainability: Derived from renewable resources, eco-friendly excipients reduce reliance on non-renewable materials, supporting a sustainable future. 2. Biodegradability: These excipients naturally break down in the environment, minimizing long-term pollution and ecological impact. 3. Reduced Toxicity: Eco-friendly excipients are generally non-toxic and safe for the environment, reducing the risk of chemical contamination. 4. Lower Carbon Footprint: Sustainable production processes for these excipients may require less energy and produce fewer greenhouse gases. 5. Improved Health Outcomes: Eco-friendly excipients enhance the stability, bioavailability, and efficacy of medications, ensuring better therapeutic results. Want to learn more about the benefits of eco-friendly excipients? Click the link to read our valuable article: https://ow.ly/cTVq50SkvkE #EcoFriendly #Pharmaceuticals #Sustainability #GreenPharmacy #HealthyLiving #BotanicalChemistPalmCove #PalmCove

ING has published an insightful report on the challenges healthcare providers face on the path to net zero emissions. Their analysis covers recommendations to reduce emissions from modernising facilities, procuring renewables, to collaborating across the value chain. In the report healthcare providers will find valuable insights into sustainable practices like energy efficiency, circularity, and engaging suppliers. Read the in-depth report here: https://buff.ly/3WL5vGJ #PPE #Healthcare #Netzero #Sustainability